Tirzepatide: The Dual GIP/GLP-1 Deep-Dive

Tirzepatide is a once-weekly synthetic peptide that activates two gut-hormone receptors, GIP and GLP-1, at the same time. Eli Lilly developed it (as LY3298176) and markets it as Mounjaro and Zepbound. In SURMOUNT-1 it produced the largest average weight loss of any approved drug in its class, and it carries an FDA label and cardiovascular outcome data.

Fat loss comes down to one thing at the core: energy in versus energy out. Take in more energy (calories) than you burn and the surplus is stored as fat; burn more than you take in and your body dips into the stores. It is basic thermodynamics, and nothing escapes it, not a peptide, not a drug. GLP-1 receptor agonists act on the "energy in" side: in trials they reduced appetite and food intake. Tirzepatide is one of the most studied tools in that class, and the energy frame is how to read everything below.

Tirzepatide is the compound that moved the goalposts. Before it, semaglutide (Ozempic, Wegovy) was the weight-loss drug everyone talked about. Then Eli Lilly put two receptors in one molecule instead of one, ran it head-to-head against semaglutide, and won outright. Today it is sold as Mounjaro for type 2 diabetes and Zepbound for obesity (and, since December 2024, for obstructive sleep apnoea), and it holds the largest weight-loss effect of any approved drug in the class.

It is also the most proven compound Primogen stocks. Retatrutide puts up bigger trial numbers, but tirzepatide has the thing retatrutide does not yet: years of Phase 3 data, an FDA label, and cardiovascular outcome credentials. This guide walks through what it is, what the data actually says, how people dose it, and where it sits next to the heavier hitter.

What is tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide that activates two of your body's gut-hormone receptors at once: GIP and GLP-1. Receptors are the docking points on your cells that a hormone plugs into to give an instruction, and GIP and GLP-1 are two of the hormones your gut releases after a meal. Activating a receptor on purpose like this is called agonism, which is why these drugs are known as agonists. The industry nickname for this is a "twincretin." Semaglutide hits GLP-1 alone. Tirzepatide adds GIP, and that second lever is what separates it from everything that came before.

Both hormones are released after eating. Mimicking them acts on several pathways at once:

• It signals satiety in the brain, the mechanism behind the "food noise" reduction users describe.
• It slows gastric emptying (most of the GI side effects trace to this).
• It acts on insulin sensitivity (how well cells respond to insulin to pull sugar out of the blood) and glucose handling, which is why the molecule started life as a diabetes drug.

The GIP component is of interest beyond the additional weight loss in trials: research suggests it may blunt the nausea associated with pure GLP-1 receptor agonists. That mechanistic combination is why tirzepatide, as Mounjaro and Zepbound, became the benchmark.

One honest note on the mechanism, because the field has not fully settled it: there is a live scientific debate about whether the GIP side works by switching the receptor on (agonism) or by tiring it out (functional antagonism via desensitisation). The clinical results are not in dispute. The exact receptor pharmacology still is.

What does the trial data on tirzepatide show?

The headline trial result is SURMOUNT-1, where participants on 5 / 10 / 15 mg lost an average -16.0% / -21.4% / -22.5% of body weight at 72 weeks versus -2.4% on placebo. Tirzepatide is about as well-evidenced as a metabolic drug gets, across two big trial programs: SURPASS (diabetes) and SURMOUNT (obesity). The numbers that matter most for weight loss:

• SURMOUNT-1 (Jastreboff, NEJM 2022, n=2,539): -16.0% / -21.4% / -22.5% average body-weight loss at 72 weeks on 5 / 10 / 15 mg, against -2.4% on placebo. The three-year extension (NEJM 2024) reported that participants who reached their low point largely held it while they stayed on the drug, and that prediabetic participants had 94% lower progression to type 2 diabetes versus placebo.
• SURMOUNT-5 (Aronne, NEJM 2025, n=751): the head-to-head trial. Tirzepatide against semaglutide 2.4 mg, -20.2% vs -13.7% at 72 weeks. That is roughly 47% more relative weight loss. About a third of the tirzepatide group lost at least a quarter of their body weight; half as many did on semaglutide.
• SURPASS-CVOT (Nicholls, NEJM 2025, n=13,299): the cardiovascular outcomes trial. Tirzepatide met its non-inferiority bar (proof it was at least no worse than the comparison treatment) for major cardiac events against an active comparator, and the trial reported significantly lower all-cause mortality and slower kidney-function decline. This is the credential retatrutide does not have yet: trial evidence on outcomes beyond the scale.

Trials have also reported findings beyond body weight:

• Liver: in SYNERGY-NASH (Loomba, NEJM 2024), 52% to 73% of patients reached resolution of liver inflammation (MASH) by dose, versus 13% on placebo.
• Sleep apnoea: the SURMOUNT-OSA trial (Malhotra, NEJM 2024) supported a first-in-class FDA approval for moderate-to-severe OSA in obesity (December 2024).
• Heart failure: the SUMMIT trial reported a 46% reduction in worsening heart-failure events in a specific obesity-related heart-failure population, with systolic blood pressure about 5 mmHg lower as a secondary finding (Borlaug, Nat Med 2025).

Two things to keep honest. Trial figures come from supervised dosing with proper titration (raising the dose gradually in steps) and dietitian support behind them, so reported results vary. And these cardiovascular and liver findings are from specific trial populations, not a promise of the same result in everyone.

Tirzepatide vs semaglutide vs retatrutide: how do they compare?

The short version: in a head-to-head trial tirzepatide outperformed semaglutide on weight loss, and retatrutide posts higher Phase 3 topline numbers than tirzepatide. The detail sits in the table below.

Against semaglutide, tirzepatide produced greater weight loss in the head-to-head trial, and roughly 5 mg of tirzepatide matched a full 2.4 mg dose of semaglutide in practice. Primogen does not stock semaglutide for that reason: it has been outclassed on the data.

Against retatrutide, the picture is more nuanced. Retatrutide adds a third receptor, glucagon, which in animal and mechanistic studies raises energy expenditure rather than acting on appetite alone. Its Phase 3 topline numbers run higher, around 28-30%. But milligram-for-milligram, tirzepatide is often reported as the stronger appetite signal, and it has the deeper safety file. There is no "earn your way up" ladder here; they are different tools. The full breakdown is in Retatrutide vs Tirzepatide vs Semaglutide, and the heavier compound gets its own Retatrutide deep-dive.

How is tirzepatide dosed and titrated?

The clinical schedule starts at 2.5 mg once weekly for four weeks (a tolerance dose, not a weight-loss dose), then steps up by 2.5 mg every four weeks or more toward a maintenance dose of 5, 10, or 15 mg weekly, with 15 mg the maximum. Tirzepatide has a roughly 5-day half-life (the time it takes for half a dose to clear the system; mean ~5.4 days; Schneck, CPT:PSP 2024) and reaches steady state, the point where the blood level stops climbing and holds steady, after about four weeks of weekly dosing. That long half-life is why it is a once-weekly compound, and why the way you climb the dose matters more than almost anything else.

The clinical schedule (how the trials ran it): start at 2.5 mg once weekly for four weeks. This starter dose is for tolerance, not for weight loss. Then step up by 2.5 mg every four weeks or more, as tolerated, toward a maintenance dose of 5, 10, or 15 mg weekly. Maximum is 15 mg. The single most important rule the trials followed was to climb slowly, since rushing the titration is associated with the worst gastrointestinal side effects.

Microdosing and split dosing. A large part of the research community runs tirzepatide differently from the label, at sub-clinical weekly doses. The pharmacology behind the split-dose idea: because the drug accumulates (~1.7x) and clears slowly, splitting a weekly dose into two smaller injections a few days apart keeps the same total weekly exposure but lowers the peak concentration, which is where acute nausea is most associated. Lower peak, in principle a smoother profile.

Practical patterns reported in the community and by Vigorous Steve include:

• Low-dose split: 0.25 mg to 1.5 mg (commonly 1 mg) three times a week (e.g. Monday/Wednesday/Friday), reported to spread exposure and reduce the late-week trough and the nausea of one big weekly dose.
• Fat-loss / pre-TRT range: roughly 3 mg to 7.5 mg weekly, ideally split. Steve reports keeping it around 3 mg weekly to limit nausea.
• Alongside hunger-inducing compounds: small weekly doses (around 1 mg, split) reported alongside growth-hormone secretagogues (compounds that prompt the body to release more growth hormone) like MK-677.
• Tapering after a diet: start as low as 0.25 mg three times weekly and taper off very slowly rather than stopping abruptly.

A hard caveat on all of that: no clinical trial has tested any dose below 2.5 mg/week. Microdosing is an extrapolation from the SURMOUNT-1 dose-response curve and it is widely practised in the community, but it is not validated efficacy. Treat it as such. And do not chase the other extreme either: megadosing (people have reported up to 35 mg weekly) is strongly discouraged and can slow gut transit severely.

If you are new to injecting and reconstituting (mixing the dry powder with liquid to make an injectable solution) lyophilised peptides, how to reconstitute and dose covers the practical side step by step.

How do you reconstitute and handle tirzepatide?

Reconstitute the lyophilised powder with bacteriostatic (BAC) water, swirl gently to dissolve, and store the mixed vial in the fridge. Tirzepatide ships as a lyophilised (freeze-dried) powder in a vial that you reconstitute yourself. Use bacteriostatic (BAC) water only. Never plain sterile water. The benzyl alcohol in BAC water is what lets you draw from the same vial over multiple days without it spoiling. Primogen supplies BAC water for exactly this.

A standard worked example for a 5 mg vial:

1. Wipe the vial stopper with an alcohol swab.
2. Slowly inject 1 ml of BAC water down the inside wall of the vial. That gives a concentration of 5 mg/ml.
3. Swirl gently to dissolve. Do not shake.
4. At 5 mg/ml, 0.2 ml draws a 1 mg dose. (For Steve's microdosing, roughly a third of a 5 mg vial is about 1.66 mg.)

Store the reconstituted vial in the fridge (2-8 C), out of light, and use within about 30 days. Inject subcutaneously, meaning into the fat just under the skin, with a short insulin needle (a 31G, 5/16-inch pin into the abdomen, thigh, or outer arm works well), and rotate sites. If you are also running BPC-157 or other injectable peptides, keep the injection sites at least an inch apart. Start low to assess tolerance and do not overshoot, an accidental large first dose is a fast track to severe vomiting.

One straight word on quality, because the industry tends to stay quiet about it. Research peptides overwhelmingly come out of China, and proper per-batch third-party testing is thin across the whole sector. Primogen does not test its own product yet, its own independent testing is on the roadmap as it scales, and it will not claim to be there already. What can be said today is that this product line has third-party tested at the supplier level on a reference basis. Read the certificate of analysis on whatever you buy, and know what it does and does not prove.

What are the side effects of tirzepatide?

The most commonly reported side effects in trials are gastrointestinal and dose-linked: nausea, vomiting, diarrhoea, and constipation, worst during titration and easing after. The profile is well-characterised, which is one of the upsides of a drug this heavily studied. The common effects, in detail:

• Nausea is the headline, affecting more than a quarter of users. It hits hardest in the first couple of weeks and flares briefly each time you step the dose up, then settles. The GIP component is thought to soften it somewhat versus pure GLP-1 drugs.
• Vomiting, diarrhoea, and constipation are all common and follow the same pattern: worst on the way up, easing as your body adapts.
• Fatigue shows up for some people as a standalone effect.

The slower-burning issues are where the real attention should go:

• Lean-mass loss. In the SURMOUNT-1 DXA substudy (Look, 2025), about 25% of total weight lost was lean mass. Tirzepatide is not a steroid and it is not anabolic. The trial literature pairs rapid weight loss with the importance of adequate protein and resistance training (commonly cited at 1.8-2.2 g/kg protein) to preserve lean mass.
• Weight regain on stopping. SURMOUNT-4 (Aronne, JAMA 2023) is the key trial here: of participants who stopped after the lead-in, 82% regained at least a quarter of what they had lost within a year, and the metabolic markers tracked back with it. The honest framing is that the trial data treats this as a long-term tool, not a one-off course.
• Heart rate rose modestly across trials of this drug class (roughly a few beats per minute). The reported increase is smaller for tirzepatide than for retatrutide.
• Bone density appeared to fall in step with weight loss rather than as a direct drug effect, with a slightly larger signal in non-diabetic users (Liu, J Clin Endocrinol Metab 2026). A DXA scan is worth considering with fast loss or postmenopausal status.
• Hair shedding (telogen effluvium) is reported. Per Dr. Ksenia (MD), GLP-1 drugs are not thought to cause it directly; it is associated with the metabolic stress of rapid weight loss, under-fuelling, and nutrient gaps (protein, iron, zinc).

Rare but serious risks are class-wide: pancreatitis and gallbladder trouble (the latter associated with rapid weight loss generally). There is also a rodent-based thyroid-tumour warning carried on the label, with unclear human relevance, and a personal or family history of medullary thyroid cancer is treated as a contraindication. A couple of flags reported by the community: heavy lifts that spike intra-abdominal pressure (leg press, reverse hypers) soon after a dose are linked to acute nausea, and the label notes that the drug class can lower blood glucose, so hypoglycaemia (blood sugar dropping too low) is a documented risk.

Why choose tirzepatide over retatrutide?

Researchers typically choose tirzepatide over retatrutide for its longer evidence base: it has the longest Phase 3 record and the only FDA label among the GLP-1 compounds Primogen stocks. The points that distinguish it:

• The FDA-approved option with the longest clinical-trial record of the stocked GLP-1s.
• The strongest milligram-for-milligram appetite signal among the leading GLP-1s, as reported in the comparative literature.
• A smaller heart-rate increase than retatrutide across trials.
• A friendlier price than the newer triple agonist.

Beyond the headline fat-loss research, the community reports running it across a few profiles: in fitness contexts for appetite management; by bodybuilders in cutting blocks (commonly 5-7.5 mg/week, discontinued a couple of weeks before a contest so gut motility recovers for the carb-up); and by the wellness and longevity crowd at sub-clinical microdoses, focused on the insulin-sensitivity and cardiometabolic mechanisms rather than maximum weight loss. None of the sub-clinical patterns are trial-validated.

For maximum raw potency and the broadest metabolic effects on a newer compound, retatrutide is the heavier tool. For the most proven, best-tolerated, better-value option, tirzepatide is the pick, which is why it stays on the shelf here.

Produk terkait

Tirzepatide

Rp 1.990.000 · 30mg